DUBLIN, November 22, 2017 /PRNewswire/ --
The "Global Premature Ejaculation Treatment Market 2017-2021" report has been added to Research and Markets' offering.
The global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.
Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The latest trend gaining momentum in the market is Growing online retail sales of drugs. The advent of the internet has reduced the time involved in the physical buying and selling of products and services for buyers and sellers. In terms of growth of different retail channels through which sexual disorder-related drugs are offered, online retailing will be the fastest channel of distribution during the forecast period. The success of online retailing can be attributed to factors such as the availability of a broad range of products, quick delivery services, and highly competitive prices.
According to the report, one of the major drivers for this market is High use of off-label drugs. The global premature ejaculation treatment market has witnessed the increased use of off-label drugs belonging to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Pharmacological modification of the ejaculatory response in patients with the condition represents a novel approach for the treatment of premature ejaculation and will lead to the gradual replacement of psychosexual counseling, which was previously regarded as the cornerstone of premature ejaculation treatment.
Further, the report states that one of the major factors hindering the growth of this market is Alternative treatments. While the market has several drugs in the pipeline, the growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease. Some of the alternate treatment methods include counseling, homeopathy, psychotherapy, yoga, and herbal therapy. There are also other natural treatment options for premature ejaculation such as ginseng tea or supplement, raw almond milk, and Ayurvedic dietary changes that can help in delaying ejaculation.
Key Market Trends
- Growing online retail sales of drugs
- Increase in awareness of premature ejaculation
- New treatment methods
Key vendors
- Absorption Pharmaceuticals
- Bayer
- Eli Lilly
- Regent Pacific Group
Other prominent vendors
- Dong-A Pharmaceutical
- Emcure
- Futura Medical
- GlaxoSmithKline
- NeuroHealing Pharmaceuticals
- Pfizer
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Premature Ejaculation: Disease Overview
Part 06: Market Landscape
Part 07: Pipeline Landscape
Part 08: Market Segmentation By Route Of Administration
Part 09: Market Segmentation By Drug Class
Part 10: Regional Landscape
Part 11: Decision Framework
Part 12: Drivers And Challenges
Part 13: Market Trends
Part 14: Vendor Landscape
Part 15: Key Vendor Analysis
Part 16: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/dlvf7c/global_premature
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article